Mountain Valley MD Holdings Inc. (MVMD) closed out 2025 with significant advancements across its three core technological platforms: nutraceuticals, agriculture, and animal health. The company, traded on the CSE, OTCQB, and FRA, highlighted progress in product development, field validation, and foundational commercial strategies, positioning itself for sustained growth in the coming year.
**Nutraceuticals: Quicksome™ Technology Driving Innovation**
At the heart of MVMD’s nutraceutical endeavors is its patented Quicksome™ technology. This innovative liposomal delivery system is engineered to encapsulate active ingredients, optimizing their absorption and efficacy, particularly in sublingual and dermal applications. The technology’s ability to enhance precise dosing, reduce variability, and enable dose sparing makes it a compelling proposition for partners in the competitive health and wellness market.
MVMD has solidified its manufacturing capabilities through an exclusive arrangement with a U.S.-based GMP production partner. This facility is equipped to handle Quicksome™ sublingual and dermal formulations, supporting both MVMD’s proprietary “Mountains Of…” product line and its licensing agreements.
The company reported continued success with its licensee, Circadian Wellness Corp. Products like “Eons Dialed” and “Eons Deeper Sleep,” which leverage Quicksome™ technology, have experienced positive consumer reception and consistent sales volumes throughout 2025.
Beyond existing partnerships, MVMD has been actively pursuing new licensing opportunities. Novel formulations are under development for a range of human health benefits, including relief for hot flashes and night sweats in menopausal women, post-workout muscle recovery, anti-inflammation, and joint health. Furthermore, discussions are progressing with a U.S.-based multi-level marketing client for a fenugreek glycosides testosterone formulation utilizing Quicksome™ quick-dissolve tablet technology. This formulation has shown promising results in performance and taste, with a projected launch in early 2026.
MVMD’s “Mountains Of…” brand continues to secure U.S. trademark protection across various categories, including Sleep, Energy, Relief, Libido, and Lean, supporting ongoing sample development and business development initiatives. Distribution partners have the flexibility to market MVMD’s branded products or develop their own white-label versions.
**Agriculture: Agrarius™ Technology Shows Promise in Sustainable Farming**
The agricultural division of MVMD is focused on the licensed distribution of Agrarius™, a plant signaling technology designed to enhance crop yields organically while potentially reducing the need for fertilizers and pesticides. The company holds exclusive distribution rights for Agrarius™ across North America, Central America, South America, and the Caribbean.
Agrarius™ is applied via sprayer at critical stages of plant growth and has demonstrated positive results across a diverse range of crops and environments.
**Brazil Citrus Trials Yield Impressive Results**
In Brazil, MVMD collaborated with agricultural partner FARMATAC on trials involving both mature and young citrus orchards. The results from mature Hamlin and Valencia orange trees were particularly encouraging:
* **Hamlin Variety:** Treated orchards saw an approximate 15% increase in productivity per hectare, with a total yield increase of about 22% due to improved juice extraction. Agronomists also noted a visual reduction in symptoms associated with Huanglongbing (HLB), or citrus greening disease.
* **Valencia Variety:** Treated blocks achieved an average yield increase of 49%, with enhanced tree vigor and canopy density suggesting improved nutrient uptake and photosynthetic activity.
Further trials on younger citrus trees yielded even more compelling outcomes. Agrarius™-treated young orchards exhibited significantly stronger plant vigor, improved flowering and fruit set, enhanced stress resilience (including during dry periods), and substantially higher productivity. Pera varietals, in particular, saw productivity gains exceeding 50%. These findings suggest Agrarius™’s potential to positively impact crop lifecycles from early development and mitigate yield variability in the face of challenging climatic conditions.
“The Brazil citrus trial demonstrates that Agrarius™, under real farm conditions and third-party monitoring, delivered substantial yield improvements, stronger plant health, and meaningful mitigation of Greening stress in citrus,” stated Dennis Hancock, President and CEO of Mountain Valley MD. “We believe the findings will support commercial expansion in 2026, positioning Agrarius as a high-impact, low-disruption tool for Brazilian citriculture.” The consistent observation of reduced HLB symptoms across these trials, including in younger orchards, is viewed as a significant indicator of Agrarius™’s potential as an organic tool for growers managing citrus greening.
**Broader Crop Validation and LATAM Expansion**
Beyond citrus, Agrarius™ trials in Brazil and Colombia, conducted in partnership with universities, agronomy labs, and farmer networks, have yielded positive results across various crops:
* **Corn:** Yield gains of approximately 14.8% and 11.2% were observed, linked to improved chlorophyll concentration and root development.
* **Sugarcane:** Yield improvements of 8 to 12 tons per hectare, increased sugar content, and reduced pest damage were reported.
* **Soybeans:** Average yield gains of 6.34 sacs per hectare were achieved across 14 farmer validations.
* **Cotton:** Increases in bolls per plant and overall yield were supported by improved photosynthetic efficiency.
* **Potatoes:** Productivity increases of approximately 18.5% were noted in summer harvest trials.
Notably, Agrarius™-treated crops in Brazil demonstrated significantly lower yield losses during extended dry periods compared to untreated controls, highlighting the product’s potential to enhance water-use efficiency and maintain productivity under drought stress.
In Colombia, MVMD is finalizing a large-scale pasture grass productivity program with FEDEGAN, expected to yield preliminary results in early 2026.
**Husbandry Animals and Aquatic Species: Soluvec™ 1% Strategic Review**
MVMD’s patented Quicksol™ solubilization technology has been applied to ivermectin to create Soluvec™ 1%, a formulation designed for safer and more effective administration in husbandry animals and aquatic species. The formulation has demonstrated nine-month stability at various temperatures and remains MVMD’s primary commercial asset within the Quicksol™ platform.
The company’s commercialization strategy for Soluvec™ 1% has centered on third-party licensing. In Bangladesh, an exclusive license agreement was established for the manufacture and distribution of Soluvec™ 1% products in injectable and feed coating formats, with royalty payments based on net sales. While this initial deployment demonstrated large-scale manufacturing capabilities, royalty revenues and overall commercial traction in 2025 fell short of expectations, partly due to market disruptions.
MVMD is currently undertaking a strategic review of its Soluvec™ 1% licensing structure, exploring options to modify or restructure territorial exclusivity in Bangladesh to better align with partners capable of driving commercialization. The company intends to prioritize low-capital, royalty-based licensing opportunities, avoiding direct investment in manufacturing or market development. Discussions with potential new licensees in Latin America are underway, where demand for scalable and cost-effective animal health solutions is high, and MVMD’s patent strategy offers support for future commercial development.
The company believes that a more selective and partner-aligned approach will better position Soluvec™ for sustainable royalty growth, supported by peer-reviewed data demonstrating improved bioavailability, efficacy, and stability compared to conventional ivermectin formulations.
**About Mountain Valley MD Holdings Inc.**
Mountain Valley MD Holdings Inc. is focused on building a world-class organization through the implementation, licensing, and reselling of key technologies, including its patented Quicksome™ oral formulation and delivery technologies, patented Quicksol™ solubility formulation technology, and its licensed reseller agreement for Agrarius™, a novel agricultural plant signaling technology. The company’s vision, “More Life,” underpins its efforts to develop advanced delivery solutions for molecules in human and animal applications, addressing areas such as pain management, weight loss, energy, focus, sleep, and anxiety. MVMD’s work with Agrarius™ aims to positively impact crop yields and reduce fertilizer usage.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/14975.html
